Silva Maria P, Ferreira Luísa T, Brás Natércia F, Torres Lurdes, Brandão Andreia, Pinheiro Manuela, Cardoso Marta, Resende Adriana, Vieira Joana, Palmeira Carlos, Martins Gabriela, Silva Miguel, Pinto Carla, Peixoto Ana, Silva João, Henrique Rui, Maia Sofia, Maiato Helder, Teixeira Manuel R, Paulo Paula
Cancer Genetics Group, IPO Porto Research Center (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center, Porto, Portugal.
LAQV, REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal.
J Biomed Sci. 2024 Jul 16;31(1):74. doi: 10.1186/s12929-024-01056-z.
Prostate cancer (PrCa) is the most frequently diagnosed cancer in men. Variants in known moderate- to high-penetrance genes explain less than 5% of the cases arising at early-onset (< 56 years) and/or with familial aggregation of the disease. Considering that BubR1 is an essential component of the mitotic spindle assembly checkpoint, we hypothesized that monoallelic BUB1B variants could be sufficient to fuel chromosomal instability (CIN), potentially triggering (prostate) carcinogenesis.
To unveil BUB1B as a new PrCa predisposing gene, we performed targeted next-generation sequencing in germline DNA from 462 early-onset/familial PrCa patients and 1,416 cancer patients fulfilling criteria for genetic testing for other hereditary cancer syndromes. To explore the pan-cancer role of BUB1B, we used in silico BubR1 molecular modeling, in vitro gene-editing, and ex vivo patients' tumors and peripheral blood lymphocytes.
Rare BUB1B variants were found in ~ 1.9% of the early-onset/familial PrCa cases and in ~ 0.6% of other cancer patients fulfilling criteria for hereditary disease. We further show that BUB1B variants lead to decreased BubR1 expression and/or stability, which promotes increased premature chromatid separation and, consequently, triggers CIN, driving resistance to Taxol-based therapies.
Our study shows that different BUB1B variants may uncover a trigger for CIN-driven carcinogenesis, supporting the role of BUB1B as a (pan)-cancer predisposing gene with potential impact on genetic counseling and treatment decision-making.
前列腺癌(PrCa)是男性中最常被诊断出的癌症。已知的中等到高外显率基因中的变异仅能解释不到5%的早发性(<56岁)和/或具有家族聚集性的病例。鉴于BubR1是有丝分裂纺锤体组装检查点的重要组成部分,我们推测单等位基因BUB1B变异可能足以引发染色体不稳定(CIN),从而潜在地触发(前列腺)致癌作用。
为了揭示BUB1B作为一个新的前列腺癌易感基因,我们对462例早发性/家族性前列腺癌患者的生殖系DNA以及1416例符合其他遗传性癌症综合征基因检测标准的癌症患者进行了靶向二代测序。为了探究BUB1B在泛癌中的作用,我们使用了计算机模拟的BubR1分子建模、体外基因编辑以及患者的离体肿瘤和外周血淋巴细胞。
在约1.9%的早发性/家族性前列腺癌病例和约0.6%的符合遗传性疾病标准的其他癌症患者中发现了罕见的BUB1B变异。我们进一步表明,BUB1B变异导致BubR1表达和/或稳定性降低,进而促进过早染色单体分离增加,从而引发CIN,导致对基于紫杉醇的治疗产生耐药性。
我们的研究表明,不同的BUB1B变异可能揭示了CIN驱动的致癌作用的触发因素,支持BUB1B作为一个(泛)癌易感基因的作用,这可能对遗传咨询和治疗决策产生潜在影响